Examples of using Described in version in English and their translations into Greek
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Financial
-
Official/political
-
Computer
The MAH must ensure that the system of pharmacovigilance, as described in version 3.0 presented in Module 1.8.1. of the Marketing Authorisation Application, is in place and functioning before and a.
The MAH must ensure that the system of pharmacovigilance, as described in version 1.1 presented in Module 1.8.1. of the Marketing Authorisation,
The MAH must ensure that the system of pharmacovigilance, as described in version 3 presented in Module 1.8.1. of the Marketing Authorisation Application, is in place and functioning before and whilst the product is on the market.
The MAH must ensure that the system of pharmacovigilance, as described in version 2 presented in Module 1.8.1. of the Marketing Authorisation Application,
The MAH must ensure that the system of pharmacovigilance, as described in version 4.3 presented in Module 1.8.1. of the Marketing Authorisation Application,
The MAH must ensure that the system of pharmacovigilance, as described in version 3 presented in Module 1.8.1. of the Marketing Authorisation Application,
The MAH must ensure that the system of pharmacovigilance, as described in version 4.0 presented in Module 1.8.1. of the Marketing Authorisation Application,
Pharmacovigilance system The MAH must ensure that the system of pharmacovigilance, as described in version 2.0 presented in Module 1.8.1. of the Marketing Authorisation,
The Marketing Authorisation Holder must ensure that the system of pharmacovigilance, as described in version 1 presented in Module 1.8.1. of the Marketing Authorisation,
The MAH must ensure that the system of pharmacovigilance, as described in version v.003/ 20071203 presented in Module 1.8.1. of the Marketing Authorisation Application,
Pharmacovigilance system The MAH must ensure that the system of pharmacovigilance, as described in version 2.0 presented in Module 1.8.1. of the Marketing Authorisation Application,
Pharmacovigilance system The MAH must ensure that the system of pharmacovigilance, as described in version 3 presented in Module 1.8.1. of the Marketing Authorisation Application,
Pharmacovigilance system The MAH must ensure that the system of pharmacovigilance, as described in version 2.0 presented in Module 1.8.1. of the Marketing Authorisation Application,
Pharmacovigilance system The MAH must ensure that the system of pharmacovigilance, as described in version 1.0 presented in Module 1.8.1. of the Marketing Authorisation Application,
The MAH must ensure that the system of pharmacovigilance, as described in version 3 dated September 2007 presented in Module 1.8.1. of the Marketing Authorisation Application,
Pharmacovigilance system The MAH must ensure that the system of pharmacovigilance, as described in version 002 presented in Module 1.8.1. of the Marketing Authorisation Application,
Pharmacovigilance system The MAH must ensure that the system of pharmacovigilance, as described in version 3 presented in Module 1.8.1. of the Marketing Authorisation Application,
Pharmacovigilance system The MAH must ensure that the system of pharmacovigilance, as described in version 4.0 presented in Module 1.8.1. of the Marketing Authorisation Application, is in place and functioning before and whilst the product is on the market.
Pharmacovigilance system The MAH must ensure that the system of pharmacovigilance, as described in version 1.0 presented in Module 1.8.1. of the Marketing Authorisation Application,
Pharmacovigilance system The MAH must ensure that the system of pharmacovigilance, as described in version 5 presented in Module 1.8.1. of the Marketing Authorisation Application,